As of June 12, 2025, Vericel Corp (VCEL) reports a Net Margin of 4.37%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Vericel Corp's Net Margin
Over recent years, Vericel Corp's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | 4.37% |
| 2023-12-31 | -1.61% |
| 2022-12-31 | -10.16% |
| 2021-12-31 | -4.80% |
| 2020-12-31 | 2.33% |
This slight upward trend highlights how Vericel Corp manages its overall profitability and cost control over time.
Comparing Vericel Corp's Net Margin to Peers
To better understand Vericel Corp's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Vericel Corp (VCEL) | 4.37% |
| Agios Pharmaceuticals Inc (AGIO) | 1845.92% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| MiMedx Group Inc (MDXG) | 12.16% |
| MannKind Corp (MNKD) | 9.66% |
Compared to its competitors, Vericel Corp's Net Margin is among the highest compared to peers, suggesting strong overall cost management and pricing power.